BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19364831)

  • 1. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans.
    Lee SJ; Lee SS; Jung HJ; Kim HS; Park SJ; Yeo CW; Shin JG
    Drug Metab Dispos; 2009 Jul; 37(7):1464-70. PubMed ID: 19364831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
    Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
    Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
    Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
    Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
    Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.
    Kiyotani K; Shimizu M; Kumai T; Kamataki T; Kobayashi S; Yamazaki H
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1065-8. PubMed ID: 20700584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
    Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
    Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.
    Kubota T; Yamaura Y; Ohkawa N; Hara H; Chiba K
    Br J Clin Pharmacol; 2000 Jul; 50(1):31-4. PubMed ID: 10886115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.
    Tateishi T; Chida M; Ariyoshi N; Mizorogi Y; Kamataki T; Kobayashi S
    Clin Pharmacol Ther; 1999 May; 65(5):570-5. PubMed ID: 10340923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.
    Davaalkham J; Hayashida T; Tsuchiya K; Gatanaga H; Nyamkhuu D; Oka S
    Drug Metab Dispos; 2009 Oct; 37(10):1991-3. PubMed ID: 19581387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations.
    Zuo LJ; Guo T; Xia DY; Jia LH
    Genet Test Mol Biomarkers; 2012 Feb; 16(2):102-8. PubMed ID: 22224559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.
    Salazar-Flores J; Torres-Reyes LA; Martínez-Cortés G; Rubi-Castellanos R; Sosa-Macías M; Muñoz-Valle JF; González-González C; Ramírez A; Román R; Méndez JL; Barrera A; Torres A; Medina R; Rangel-Villalobos H
    Genet Test Mol Biomarkers; 2012 Sep; 16(9):1098-104. PubMed ID: 22913530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
    Coller JK; Krebsfaenger N; Klein K; Endrizzi K; Wolbold R; Lang T; Nüssler A; Neuhaus P; Zanger UM; Eichelbaum M; Mürdter TE
    Br J Clin Pharmacol; 2002 Aug; 54(2):157-67. PubMed ID: 12207635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
    Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
    Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.